WoodTrust Financial Corp acquired a new stake in Bristol-Myers Squibb Co (NYSE:BMY) in the 4th quarter, HoldingsChannel reports. The fund acquired 8,128 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Convergence Investment Partners LLC bought a new stake in Bristol-Myers Squibb in the second quarter valued at approximately $4,390,000. Dividend Assets Capital LLC bought a new stake in Bristol-Myers Squibb in the second quarter valued at approximately $737,000. Accredited Investors Inc. boosted its holdings in Bristol-Myers Squibb by 6.8% in the second quarter. Accredited Investors Inc. now owns 16,136 shares of the biopharmaceutical company’s stock valued at $899,000 after acquiring an additional 1,023 shares during the last quarter. Pinnacle Financial Partners Inc. boosted its holdings in Bristol-Myers Squibb by 73.4% in the second quarter. Pinnacle Financial Partners Inc. now owns 39,050 shares of the biopharmaceutical company’s stock valued at $2,175,000 after acquiring an additional 16,536 shares during the last quarter. Finally, Ridgewood Investments LLC boosted its holdings in Bristol-Myers Squibb by 1.6% in the second quarter. Ridgewood Investments LLC now owns 12,568 shares of the biopharmaceutical company’s stock valued at $700,000 after acquiring an additional 199 shares during the last quarter. 69.82% of the stock is owned by institutional investors.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $66.53 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05. The firm has a market capitalization of $109,954.46, a P/E ratio of 112.76, a PEG ratio of 2.09 and a beta of 1.09.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 3.9% on a year-over-year basis. research analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.40%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the stock in a transaction dated Friday, December 15th. The shares were bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.
Several brokerages recently commented on BMY. Citigroup set a $78.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, February 16th. BMO Capital Markets set a $51.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Wednesday, February 14th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price on the stock in a report on Thursday, February 1st. Piper Jaffray Companies reiterated a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Finally, Leerink Swann increased their price target on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $66.73.
TRADEMARK VIOLATION WARNING: “WoodTrust Financial Corp Acquires New Position in Bristol-Myers Squibb Co (BMY)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/woodtrust-financial-corp-acquires-new-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.